Mar 12 2010
“The agreement with Rhythm is a clear catalyst for the development of
proprietary molecules from Ipsen in promising indications within the
area of metabolic diseases, which are outside of our core strategic focus”
Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biotechnology
specialty care group, and Rhythm Pharmaceuticals (Rhythm), a
biotechnology company developing peptide therapeutics for metabolic
diseases, announced today that they have concluded a license agreement
for Ipsen’s proprietary peptide therapeutics targeting obesity,
metabolic diseases, and gastrointestinal disorders. Under the terms of
the agreement, Ipsen has granted Rhythm an exclusive worldwide license
for research, development, and commercialization of its melanocortin and
ghrelin programs originating from Ipsen research.
“The agreement with Rhythm is a clear catalyst for the development of
proprietary molecules from Ipsen in promising indications within the
area of metabolic diseases, which are outside of our core strategic focus,”
said Stéphane Thiroloix, Executive Vice President, Corporate
Development, Ipsen. “Given Rhythm’s complete focus on metabolic
diseases, this transaction will leverage our combined expertise and
resources to rapidly transform these important discoveries into valuable
medical treatments.”
“Rhythm has a great opportunity to develop significant new peptide
therapeutics to improve the health of people with obesity, diabetes, and
other intractable metabolic diseases,” said Bart Henderson,
President of Rhythm. “We are extremely fortunate to have access
to Ipsen’s peptide discoveries and expertise in peptide formulations to
help us achieve this vision.”
Source Ipsen
Neuritin 1 unlocks new pathway to treat obesity without reducing food intake